HOME >> MEDICINE >> NEWS
Selective and nonselective beta-blockers equally effective in preventing sudden death

s we move into development of the next generation of these drugs."

The selective beta-blocker used was metoprolol. The nonselective drugs were carvedilol and bucindolol. The scientists found that all the patients had approximately the same reduction in QTc dispersion. The QT interval is the time between the Q and T peaks on an ECG. QTc dispersion is the maximal difference between the shortest and longest QT. When the difference is shortened, it shows the drug has improved the health of the heart and reduced the risk of sudden death.

Beta-blockers are designed to impede the action of a cellular protein called a beta receptor. It is part of a biochemical process that regulates the heart. The receptor inhibition by the drug blocks the toxic effects of the sympathetic nervous system on the heart. Both the selective and nonselective beta-blockers used in this study appeared to alter ventricular function of the heart.

The other researchers involved in this study were UT Southwestern medical resident Dr. Susan Fesmire; VA research nurse Lucille Marcoux; research assistants Debra Lyyski and Michael Sprague; and Dr. Harold Kennedy, a professor of medicine at the University of Minnesota Medical School - Minneapolis.


'"/>

Contact: Susan Steeves
susan.steeves@email.swmed.edu
214-648-3404
UT Southwestern Medical Center
31-Aug-1999


Page: 1 2

Related medicine news :

1. Selective coatings create biological sensors from carbon nanotubes
2. Selective inhibitor can target specific enzyme that promotes cancer
3. In heart failure, beta-blockers boost survival advantage for women
4. Wider use of beta-blockers after heart attacks could save thousands of lives at a reasonable cost, new study shows
5. Aspirins potential ability to prevent colon polyps may not apply equally to all
6. New guidelines conclude all aerosol therapy devices equally effective
7. Baby and coated aspirin equally effective in thinning of blood when taken in combination with Plavix
8. Beta-blocker or calcium antagonist-based therapies equally effective in treating hypertension
9. Smoking cessation success equally good with over-the-counter or prescription nicotine replacement
10. Strategy effective against drug resistant tuberculosis
11. Study shows patch therapy may be as effective as oral medications

Post Your Comments:
(Date:5/21/2013)... Today, Zane Benefits, Inc. published a ... accounts. Zane Benefits, which provides comprehensive and flexible alternatives ... in defined contribution and http://HRA ... to Zane Benefits’ website, the Affordable Care Act (known ... in 2010 and impacts many areas of health care ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Two executives ... Guidance (SBG) will identify which strategies can be most ... high-quality care to the members who are taking them, ... Services, Inc., “How to Manage Specialty Drugs to ... pharmaceuticals are now the main driver for rising prescription ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 While North ... synonymous with comprehensive travel guides. Brunswick Plantation & Golf ... packages that include access to 27 holes of "Top10" ... courses in North Carolina, knowing the Top 10 ... Lodges takes away the overwhelming task of selecting the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Octo ... technology and management consulting solutions to the Federal ... Business Development. In the newly created role, ... all aspects of the firm’s business development function ... proposal management functions, and leading strategies to achieve ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) ... therapy for patients having severe bouts of chronic obstructive ... days of glucocorticoid treatment with prednisone to treat COPD ... but with fewer chances for adverse side effects, they ... period of treatment was not less effective than 14 ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 3
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May 21, ... and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that ... online the positive Phase 2a study results of dupilumab ... an investigational monoclonal antibody targeting the alpha subunit of ... of both IL-4 and IL-13, drivers of Th2 (Type ...
(Date:5/21/2013)... Calif. , May 21, 2013 Abaxis, ... blood analysis systems, announced today that Martin ... at the Stifel Annual Dental & Veterinary Conference on ... conference will be held at Le Parker Meridien Hotel ... About Abaxis Abaxis develops, manufactures, markets ...
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ...   Summary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
Cached News: